Leading scientific expertise
We combine a unique range of knowledge, skills and experience with a passion for following the science. In the last five years, we have invested more than 25 billion dollars in research and development (as of 2019). Our R&D is focused on three therapy areas where we believe we can make the most meaningful difference to patients: Oncology; Cardiovascular, Renal and Metabolism; and Respiratory.
Here are some examples of our key capabilities:
Our scientific heritage is grounded in pushing the boundaries of small molecule discovery and development. For decades, our scientists have led the way in identifying chemical leads. Our early discovery and high throughput screening capabilities enable us to screen thousands of compounds a day to identify molecules with potential inhibit or activate the target
Biologics have revolutionized medicine, treating complex diseases including various types of cancer and autoimmune disorders. Biologics are in development across all out therapy areas and now for half our pipeline. Much of our biologics work focuses on specifically defined populations, determined by the pathway of the disease and mode of action of the molecule.
We aim to provide industry-leading devices that are easy to use and improve the lives of patients. This includes smart technology-enabled devices that improve patient outcomes through intelligent solutions such as patient feedback to support correct use, dose reminders and disease progression and monitoring. Along with inhalation devices we are also exploring how to better meet patient needs in non-oral, non-inhaled therapies across our main therapy areas.
Immuno-oncology is a promising therapeutic approach that harnesses the patient’s own immune system to help fight cancer. Our strategy is to develop novel combinations that target each of the escape mechanisms used by tumor cells to evade the immune system. Our immune-oncology pipeline contains molecules that enhance immune response, tumor destruction or immune cell memory and compounds that target the tumor microenvironment.
As leader in personalized healthcare, we are committed to matching new medicines to the patients most likely to benefit. We combine industry-leading expertise in companion diagnostics with laboratory science in molecular diagnostics, tissue diagnostics, imaging and protein biomarkers. This includes working collaboratively with our external partners to harness break-through technologies across the life-cycle of our medicines.
Emerging drug discovery
Our teams work alongside the world’s leading academic and biotech research institution to stimulate innovation and evaluate emerging technologies. By combining the great science happening in our labs with the best external science, we can accelerate drug discovery and development across our main therapy areas. Today, our teams are working in pioneering fields such as modified RNA and genome editing with CRISPR.
CH-2306 ; 03/2020